Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum

23 Aug 2021

Abstract excerpt

Heart failure (HF) is a complex syndrome caused by a variety of structural or functional cardiac abnormalities as a consequence of several involved pathophysiological pathways. In the last decades, left ventricular ejection fraction (LVEF) has represented the principal criterion used to stratify HF, to interpret ventricular function and to identify therapeutic strategies. However, this chimeric parameter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac electrophysiology and arrhythmias
Share to Heart Failure Treatment and Management
Share to Receptor Mechanisms and Signaling

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34497530
DOI: 10.3389/fphys.2021.652163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction SpectrumPMID 34497530Read ↗

Sacubitril-Valsartan and Its Results for the Treatment of Heart Failure with Preserved and Mildly Reduced Ejection FractionSemantic proximity Read ↗

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.Semantic proximity Read ↗

Sacubitril-valsartan in Heart Failure With Preserved Ejection Fraction Following Acute Coronary SyndromeSemantic proximity Read ↗

Recent advances in the treatment of chronic heart failureSemantic proximity Read ↗

Efficacy and safety of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and hypotensionSemantic proximity Read ↗

Unraveling the Complexity: From Molecular Subtypes to Therapeutic Strategies in Heart Failure with Preserved Ejection Fraction and Atrial FibrillationSemantic proximity Read ↗

Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach.Semantic proximity Read ↗

Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment.Semantic proximity Read ↗

Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches.Semantic proximity Read ↗

New Management Strategies in Heart Failure.Semantic proximity Read ↗

Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.Semantic proximity Read ↗

Canadian Cardiovascular Society-Canadian Heart Failure Society Focused Clinical Practice Update of Patients With Differing Heart Failure Phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.